- Home
- FTHM vs SCYX Comparison
FTHM vs SCYX Comparison
Compare FTHM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- SCYX
- Stock Information
- Founded
- FTHM 2010
- SCYX 1999
- Country
- FTHM United States
- SCYX United States
- Employees
- FTHM N/A
- SCYX N/A
- Industry
- FTHM Real Estate
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- SCYX Health Care
- Exchange
- FTHM Nasdaq
- SCYX Nasdaq
- Market Cap
- FTHM 38.3M
- SCYX 34.9M
- IPO Year
- FTHM 2020
- SCYX 2014
- Fundamental
- Price
- FTHM $2.03
- SCYX $0.84
- Analyst Decision
- FTHM
- SCYX
- Analyst Count
- FTHM 0
- SCYX 0
- Target Price
- FTHM N/A
- SCYX N/A
- AVG Volume (30 Days)
- FTHM 1.2M
- SCYX 167.5K
- Earning Date
- FTHM 08-12-2025
- SCYX 08-13-2025
- Dividend Yield
- FTHM N/A
- SCYX N/A
- EPS Growth
- FTHM N/A
- SCYX N/A
- EPS
- FTHM N/A
- SCYX N/A
- Revenue
- FTHM $390,032,000.00
- SCYX $3,257,000.00
- Revenue This Year
- FTHM $25.22
- SCYX $422.61
- Revenue Next Year
- FTHM $16.19
- SCYX $240.56
- P/E Ratio
- FTHM N/A
- SCYX N/A
- Revenue Growth
- FTHM 19.16
- SCYX N/A
- 52 Week Low
- FTHM $0.65
- SCYX $0.66
- 52 Week High
- FTHM $3.37
- SCYX $1.66
- Technical
- Relative Strength Index (RSI)
- FTHM 61.01
- SCYX 55.50
- Support Level
- FTHM $1.72
- SCYX $0.82
- Resistance Level
- FTHM $2.54
- SCYX $0.88
- Average True Range (ATR)
- FTHM 0.35
- SCYX 0.04
- MACD
- FTHM 0.08
- SCYX -0.00
- Stochastic Oscillator
- FTHM 47.26
- SCYX 53.61
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.